Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
2025 Sep;7(9):e70103
In the 28-week, phase three randomized control trial (RCT) DURATION-8, dual therapy with an SGLT2 inhibitor (dapagliflozin) and a GLP-1RA (once-weekly exenatide) was shown to reduce HbA1c by 0.4% more than either agent alone, in patients with a starting HbA1c of between 8-12% 50 , illustrating that the glycemic response to dual therapy is less than additive 50
Novel Agents and Future Directions The therapeutic pipeline continues to expand with increasingly sophisticated mechanisms
Research also indicates that people who take these medications are at increased risk of gastrointestinal events, such as pancreatitis, bowel obstruction, or gastroparesis
US$ 22.79
US$ 24.35
US$ 25.56
US$ 24.10
US$ 20.75
US$ 26.21
US$ 29.48
